Company Aggregate Debt: celcuity.com (CELC)

Celcuity Inc. relies on third-party logistics providers for the transport of biosamples, mitigating risks through contractor redundancy. Personalized diagnostic systems ensure a steady cash flow via multi-year patient monitoring. The oncology analysis sector is not subject to seasonality or macro shocks. This debt movement chart demonstrates financial stability, where the 0.00 metric determines the company's current borrowing level.

Company Aggregate Debts: Celcuity (CELC) for 07/04/2022 - 10/28/2026

Analytical breakdowns and data insights for company Celcuity (CELC)

- price and consensus price forecast:

Stock Price Celcuity Therapeutics|CELC - Price Target Chart

- market capitalization data:

Market Capitalization Celcuity Corp|CELC - Enterprise Value

- book capitalization data:

Accounting Value per Share Celcuity|CELC - Book Capitalization|Market-to-Book Ratio celcuity.com|CELC - Aggregate Company Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio Celcuity Inc.|CELC - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Celcuity Inc|CELC - Company Aggregate Debts|Debts to Book Capitalization Celcuity Corp

General company analysis:Celcuity Therapeutics CELC

Celcuity Inc. invests in the development of targeted oncology drugs and cellular analysis, which requires significant capital to fund R&D cycles. The total volume of all liabilities, reflected through current debt, measures the company's aggregate debt leverage, allowing investors to assess the balance between the expansion rate of the biopharmaceutical business and the risks of losing financial stability in the absence of operating profit.

Competitors of Celcuity Inc. (CELC)